HR Execs on the Move

Imvax

www.imvax.com

 
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.imvax.com
  • 601 Walnut Street Suite 440 West
    Philadelphia, PA USA 19106
  • Phone: 267.900.4110

Executives

Name Title Contact Details
Arthur Howe
 Co-founder and Chief Financial Officer Profile
Josh Muntner
 Chief Financial Officer Profile
John Furey
 Chief Executive Officer Profile

Similar Companies

Deepcell

Our mission is to enable novel biological insights at the single-cell level for improved diagnosis and treatment of disease.

SAIC-Frederick

SAIC-Frederick is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

20/20 GeneSystems Inc

20/20 GeneSystems Inc is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tscan

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Seer

Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.